



## NSE INDEX WEEKLY REPORT

27 NOV - 01 DEC, 2017

[www.capitalcow.com](http://www.capitalcow.com)

Email – [info@capitalcow.com](mailto:info@capitalcow.com)

## ***NIFTY WEEKLY TREND:-***



## **NIFTY OUTLOOK**

The positive momentum continued as the Nifty ended higher for fifth straight session. Amongst the broader market indices, BSE Smallcap rose in line with benchmark indices, while BSE Midcap index underperformed, closing marginally lower. The sectoral indices exhibited a mixed trend. Auto, Consumer Discretionary and Capital Goods were the top gainers, while Metals, Telecom and Healthcare witnessed some profit taking. Amongst the global markets, the Asian indices ended in the green, while European markets were trading on a mixed note. The underlying sentiments remain positive and the index could continue to extent gains tomorrow. However, with the markets trading near the record highs, some profit taking at higher levels could take place. Volatility is expected to remain high ahead of key events like Q2FY18 GDP data, RBI monetary policy and upcoming

state elections in Gujarat. Traders should keep their leveraged positions hedged, while investors can continue to focus on quality counters on dips.

## **WEEKLY NEWS UPDATE:**

**Minda Industries** has approved further investment of 23.92 lac equity shares of Mindarika at Rs 395.6 per share, for a total consideration up to Rs. 94.7 Cr. After the acquisition of the above shares, Mindarika will become a subsidiary of the Company. Mindarika is engaged in the manufacturing of 4 wheeler switches and supplying its products to OEMs including Maruti Suzuki.

**Glenmark Pharmaceuticals** announced that the company has been granted final approval by the US FDA for HAILEY™ Fe 1/20. The medicine is a generic version of Loestrin tablets used to prevent pregnancy. Sales data for the 12 month period ending Sept 2017 for Loestrin Tablets market achieved annual sales of ~USD 116.8 mn.

**Strides Shasun** announced that its wholly owned subsidiary received approval from USFDA for Acetazolamide tablets (used to prevent and reduce symptoms of altitude sickness). The product will be launched immediately and will be marketed by Strides Pharma Inc.

## **POSITIONAL CALL:**

BUY MOTHERSUMI FUTURE @346-347 TGT 351-355 SL 343

BUY GPPL @148-150 TGT 160-170 SL 140

# DISCLAIMER

This publication has been solely prepared for the information purpose and does not constitute a solicitation to any person to buy or sell a security. While the information contained therein has been obtained from sources believed reliable investors are advised to satisfy themselves before making any investments. Capital Cow Research does not bear any responsibility for authentication of the information contained in the reports and consequently is not liable for any decision taken based on the same. Further Capital Cow Research report only provides information updates and analysis. All opinions for buying and selling are available to investors when they are registered clients of Capital Cow Research services. As a matter of practice, Capital Cow Research refrains from publishing any individual names with its reports.

IF ANY ENQUIRY:

Call Us - 07316008000 OR VISIT [www.capitalcow.com](http://www.capitalcow.com)